David Harlan to Antigens, CD
This is a "connection" page, showing publications David Harlan has written about Antigens, CD.
Connection Strength
0.523
-
Kirk AD, Tadaki DK, Celniker A, Batty DS, Berning JD, Colonna JO, Cruzata F, Elster EA, Gray GS, Kampen RL, Patterson NB, Szklut P, Swanson J, Xu H, Harlan DM. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation. 2001 Aug 15; 72(3):377-84.
Score: 0.171
-
Pechhold K, Patterson NB, Craighead N, Lee KP, June CH, Harlan DM. Inflammatory cytokines IFN-gamma plus TNF-alpha induce regulated expression of CD80 (B7-1) but not CD86 (B7-2) on murine fibroblasts. J Immunol. 1997 May 15; 158(10):4921-9.
Score: 0.128
-
Montgomery SP, Xu H, Tadaki DK, Celniker A, Burkly LC, Berning JD, Cruzata F, Elster EA, Gray G, Kampen RL, Swanson SJ, Harlan DM, Kirk AD. Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD154 in nonhuman primate renal transplantation. Transplantation. 2002 Nov 27; 74(10):1365-9.
Score: 0.047
-
Chute JP, Saini A, Wells M, Clark W, Wu A, St Louis D, Blair P, Harlan D, Kaushal S. Preincubation with endothelial cell monolayers increases gene transfer efficiency into human bone marrow CD34(+)CD38(-) progenitor cells. Hum Gene Ther. 2000 Dec 10; 11(18):2515-28.
Score: 0.041
-
Harlan DM, Kirk AD. The future of organ and tissue transplantation: can T-cell costimulatory pathway modifiers revolutionize the prevention of graft rejection? JAMA. 1999 Sep 15; 282(11):1076-82.
Score: 0.038
-
Knechtle SJ, Kirk AD, Fechner JH, Hong X, Dong Y, Hamawy MM, Harlan DM. Inducing unresponsiveness by the use of anti-CD3 immunotoxin, CTLA4-Ig, and anti-CD40 ligand. Transplant Proc. 1999 May; 31(3B Suppl):27S-28S.
Score: 0.037
-
Tadaki DK, Craighead N, Saini A, Celniker A, Burkly LC, Lee KP, Chute JP, Harlan DM, Kirk AD. Costimulatory molecules are active in the human xenoreactive T-cell response but not in natural killer-mediated cytotoxicity. Transplantation. 2000 Jul 15; 70(1):162-7.
Score: 0.010
-
Blair PJ, Riley JL, Harlan DM, Abe R, Tadaki DK, Hoffmann SC, White L, Francomano T, Perfetto SJ, Kirk AD, June CH. CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. J Exp Med. 2000 Feb 21; 191(4):651-60.
Score: 0.010
-
Herrera PL, Harlan DM, Vassalli P. A mouse CD8 T cell-mediated acute autoimmune diabetes independent of the perforin and Fas cytotoxic pathways: possible role of membrane TNF. Proc Natl Acad Sci U S A. 2000 Jan 04; 97(1):279-84.
Score: 0.010
-
Saha B, Chattopadhyay S, Germond R, Harlan DM, Perrin PJ. CTLA4 (CD152) modulates the Th subset response and alters the course of experimental Leishmania major infection. Eur J Immunol. 1998 12; 28(12):4213-20.
Score: 0.009
-
Horspool JH, Perrin PJ, Woodcock JB, Cox JH, King CL, June CH, Harlan DM, St Louis DC, Lee KP. Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4. J Immunol. 1998 Mar 15; 160(6):2706-14.
Score: 0.008
-
Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner JH, Knechtle SJ. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A. 1997 Aug 05; 94(16):8789-94.
Score: 0.008
-
Saha B, Jaklic B, Harlan DM, Gray GS, June CH, Abe R. Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig. J Immunol. 1996 Nov 01; 157(9):3869-75.
Score: 0.008